AUTOLUS THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4 USD | -1.96% |
|
-11.50% | -37.89% |
| Sales 2024 * | 30.47M 2.54B | Sales 2025 * | 71.52M 5.96B | Capitalization | 1.06B 88.69B |
|---|---|---|---|---|---|
| Net income 2024 * | -174M -14.51B | Net income 2025 * | -127M -10.59B | EV / Sales 2024 * | 12.7 x |
| Net cash position 2024 * | 678M 56.5B | Net cash position 2025 * | 585M 48.79B | EV / Sales 2025 * | 6.69 x |
| P/E ratio 2024 * |
-5.06
x | P/E ratio 2025 * |
-7.63
x | Employees | 467 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 3.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Autolus Therapeutics plc
More recommendations
More press releases
| 1 day | -1.96% | ||
| 1 week | -11.50% | ||
| Current month | -37.30% | ||
| 1 month | -35.17% | ||
| 3 months | -32.66% | ||
| 6 months | +48.70% | ||
| Current year | -37.89% |
1 week
3.96
4.71
1 month
3.966.44
Current year
3.967.45
1 year
1.697.45
3 years
1.608.23
5 years
1.6027.97
10 years
1.6053.24
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Pulé
FOU | Founder | 51 | 01/14/01 |
| Chief Executive Officer | 59 | 01/14/01 | |
Robert Dolski
DFI | Director of Finance/CFO | 54 | 07/23/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Berriman
BRD | Director/Board Member | 76 | 01/14/01 |
William Young
BRD | Director/Board Member | 79 | 15/21/15 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 01/18/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 2 M€ | -.--% | ||
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 4 | -1.96% | 2,745,490 |
| 25/24/25 | 4.08 | -3.09% | 3,872,988 |
| 24/24/24 | 4.21 | -6.03% | 2,720,848 |
| 23/24/23 | 4.48 | -1.75% | 1,723,804 |
| 22/24/22 | 4.56 | +0.88% | 1,154,024 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Calendar
14/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4
USD
Average target price
10.54
USD
Spread / Average Target
+163.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.89% | 1.06B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- AUTL Stock
